Joseph Schwartz
Stock Analyst at Leerink Partners
(3.20)
# 1,129
Out of 4,966 analysts
139
Total ratings
33.08%
Success rate
18.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KALV KalVista Pharmaceuticals | Maintains: Outperform | $18 → $20 | $13.46 | +48.59% | 6 | Jul 7, 2025 | |
| INSM Insmed | Maintains: Outperform | $100 → $115 | $136.10 | -15.50% | 4 | Jun 10, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Outperform | $4 → $12 | $6.48 | +85.19% | 4 | May 23, 2025 | |
| MAZE Maze Therapeutics | Initiates: Outperform | $28 | $14.49 | +93.24% | 1 | Feb 25, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $20 → $40 | $17.50 | +128.57% | 6 | Oct 11, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $11 → $14 | $0.49 | +2,741.49% | 2 | Sep 19, 2024 | |
| ANTX AN2 Therapeutics | Upgrades: Outperform | n/a | $1.10 | - | 3 | Jul 3, 2024 | |
| SLDB Solid Biosciences | Upgrades: Outperform | $12 | $5.48 | +118.98% | 6 | Jun 24, 2024 | |
| MREO Mereo BioPharma Group | Maintains: Outperform | $6 → $8 | $1.71 | +367.84% | 2 | Jun 20, 2024 | |
| SYBX Synlogic | Downgrades: Market Perform | $1 | $1.45 | -31.03% | 4 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $6 | $5.53 | +8.50% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $49.33 | -2.70% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $21.65 | -16.86% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $42.64 | -20.25% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $122 → $130 | $58.27 | +123.10% | 10 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $18.20 | +779.12% | 13 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $194.27 | -16.10% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.47 | +304.86% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $1.16 | +2,744.83% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $12 | $11.99 | +0.08% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $29.96 | +260.48% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $39 | $30.99 | +25.85% | 1 | May 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $4 | $1.60 | +150.00% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $14.35 | +109.06% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $50 | $46.58 | +7.34% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $59.05 | -49.20% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $56 | $16.33 | +242.93% | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $7.59 | +84.45% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $2.25 | +433.33% | 2 | Sep 26, 2017 |
KalVista Pharmaceuticals
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $13.46
Upside: +48.59%
Insmed
Jun 10, 2025
Maintains: Outperform
Price Target: $100 → $115
Current: $136.10
Upside: -15.50%
Fulcrum Therapeutics
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $6.48
Upside: +85.19%
Maze Therapeutics
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $14.49
Upside: +93.24%
Travere Therapeutics
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $17.50
Upside: +128.57%
Applied Therapeutics
Sep 19, 2024
Maintains: Outperform
Price Target: $11 → $14
Current: $0.49
Upside: +2,741.49%
AN2 Therapeutics
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.10
Upside: -
Solid Biosciences
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $5.48
Upside: +118.98%
Mereo BioPharma Group
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $1.71
Upside: +367.84%
Synlogic
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.45
Upside: -31.03%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $6
Current: $5.53
Upside: +8.50%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $49.33
Upside: -2.70%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $21.65
Upside: -16.86%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $42.64
Upside: -20.25%
Feb 3, 2023
Maintains: Outperform
Price Target: $122 → $130
Current: $58.27
Upside: +123.10%
Jan 20, 2023
Reiterates: Outperform
Price Target: $160
Current: $18.20
Upside: +779.12%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $194.27
Upside: -16.10%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.47
Upside: +304.86%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $1.16
Upside: +2,744.83%
Nov 4, 2022
Maintains: Outperform
Price Target: $17 → $12
Current: $11.99
Upside: +0.08%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $29.96
Upside: +260.48%
May 26, 2022
Maintains: Outperform
Price Target: $36 → $39
Current: $30.99
Upside: +25.85%
May 12, 2022
Maintains: Outperform
Price Target: $6 → $4
Current: $1.60
Upside: +150.00%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $14.35
Upside: +109.06%
May 11, 2022
Maintains: Outperform
Price Target: $53 → $50
Current: $46.58
Upside: +7.34%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $59.05
Upside: -49.20%
May 3, 2022
Maintains: Outperform
Price Target: $71 → $56
Current: $16.33
Upside: +242.93%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $7.59
Upside: +84.45%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $2.25
Upside: +433.33%